Drug Database
AL

alternaria allergen SLIT

✓ Approved

HAL Allergy Group · therapeutic agent

What is alternaria allergen SLIT?

alternaria allergen SLIT is a therapeutic agent developed by HAL Allergy Group. It is approved for therapeutic indications via oral (po) or sublingual (sl)/oral transmucosal.

Drug Profile

CompanyHAL Allergy Group
RouteOral (PO), Sublingual (SL)/Oral Transmucosal
StatusApproved
Sources: ClinicalTrials.gov, HAL Allergy Group

Therapeutic Indications

alternaria allergen SLIT is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Immune system disordersHypersensitivity✓ Approved

Related Research Articles

PubMedImmunological investigations2026-10-15

Rewiring Food Allergy Management: From Allergen Detection to Immune Engineering Therapies.

Meng Jiaqi J, Zhao Leyan L, Wei Qinglin Q, Wei Pengcheng P

Food allergy represents a growing global health challenge, particularly among children in developed countries. Despite decades of research, major barriers persist in both allergen detection and durable immune intervention. This review synthesizes current diagnostic and therapeutic strategies in food allergy, critically evaluates their mechanistic underpinnings and translational readiness. Traditional immunoassays (e.g. enzyme-linked immunosorbent assay, immunoblotting) are sensitive but hindered by matrix interference, operational complexity, and limited real-world applicability. Recent innovations - multi-omics, DNA-based platforms, and portable biosensors - are advancing allergen surveillance toward precision, on-site detection. In parallel, allergen-specific immunotherapies have emerged as proactive strategies for desensitization, yet vary in efficacy, safety, and sustainability. Biologics (e.g. omalizumab, dupilumab) have broadened treatment options, while next-generation platforms - virus-like particle vaccines and microbiome-augmented protocols - are unlocking novel paths toward sustained unresponsiveness. This review outlines an emerging framework of immune engineering poised to redefine the future of allergy care.

PMID 42876274
Read full article →
PubMedCatheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions2026-10-15

Impaired Flow and Physiology in Coronaries With Anomalous Origin From the Opposite Sinus of Valsalva.

Lo Rito Mauro M, Squillace Mattia M, Agnifili Mauro Luca ML, Rosato Antonio A et al.

Anomalous Aortic Origin of a Coronary Artery (AAOCA) high-risk anatomical features (intramural segment, acute take-off angle, slit-like ostium) cause coronary stenosis leading to myocardial infarction. How these features alter coronary physiology remains unclear. We aimed to evaluate their impact on coronary blood supply using continuous thermodilution. We prospectively enrolled 51 AAOCA patients undergoing continuous thermodilution. Subjects were classified into an ischemic risk (IR) group (intramural segment, acute angle, oval or slit ostium) or non-ischemic risk (no-IR) group. Non-anomalous coronary arteries served as controls. We measured absolute coronary blood flow (CBF) and microvascular resistance. Subjects (median age 48.4 years) presented mostly with angina, syncope, and arrhythmia. Final analysis included 48 AAOCA cases (31 IR, 17 no-IR) and 45 controls. The IR group had a median IM length of 9 mm, take-off angle of 31.9°, and a slit-like or oval ostium. The no-IR group had a median angle of 51.5° and an oval or round ostium. At rest, absolute CBF and microvascular resistance showed no significant differences among groups. However, during hyperemia, the IR group had significantly reduced CBF compared to controls (179 vs. 290 mL/min, p = 0.015). The IR group demonstrated higher microvascular resistance at rest (1473 vs. 1150, p = 0.024) and during hyperemia (433 vs. 305, p = 0.012), indicating persistently increased coronary vascular tone. High-risk anatomical features of AAOCA are associated with altered coronary physiology. An intramural segment, acute take-off angle, and slit-like or oval ostium are linked to reduced hyperemic coronary blood flow due to increased microvascular resistance.

PMID 42876388
Read full article →
PubMedThe Egyptian journal of immunology2026-10-15

Assessment of survivin mRNA expression level and its serum level in patients with diabetic retinopathy.

Abdelhady Shaymaa A SA, Greash Mohamed M, Karrar Mohamed M MM, Moustafa Heba M HM et al.

Diabetic patients may suffer from diabetic retinopathy (DR) which may result in vision loss. Apoptosis is essential in vascular remodeling. Survivin inhibits endothelial cell apoptosis and enhances angiogenesis. Diabetic vasculopathy can increase survivin expression. Our aim is to measure the clinical significance of survivin mRNA expression and its serum level with DR as predictors for disease prognosis. Thirty patients with DR; thirty without DR and thirty healthy persons were included as controls (employees and attendants for checkup with normal HA1c level). Ophthalmic examination, best corrected visual acuity assessment (BCVA), slit-lamp biomicroscopy, and fundoscopy, were done for all patients. DR was diagnosed by biomicroscopic fundus examination. Serum survivin level was estimated by enzyme linked immunosorbent assay (ELISA) technique and survivin messenger ribonucleic acid (mRNA) expression by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) as potential biomarkers of DR. Serum survivin was significantly increased in DR patients than those without DR (p < 0.01). Serum survivin and its mRNA expression correlated significantly and positively with HbA1c in DM patients (r = 0.808 and 0.618, p < 0.001). Serum survivin has an AUC of 0.985 (95% CI: 0.955 - 1.000, p < 0.001) with a sensitivity of 96.67% and specificity of 93.33% at a cutoff value of >360 pg/mL. For survivin mRNA expression, the AUC was 0.907 (95% CI: 0.820 - 0.995, p < 0.001) with a sensitivity of 86.67 % and specificity of 83.33 % at a cutoff value of >1.7. In conclusion, survivin mRNA expression and its serum level are elevated in patients with DR than those without DR. They showed strong positive correlation with HbA1c level. Both survivin mRNA expression and its serum level might have a marked role in the diagnosis of DR.

PMID 42875957
Read full article →
PubMedFrontiers in cardiovascular medicine2026-10-15

Primary left ventricular intimal sarcoma: a case report of multimodality imaging and molecular confirmation.

Peng Peiyan P, Wang Liangyu L, Li Bingli B, Yao Peixiu P et al.

Primary cardiac intimal sarcoma is a rare malignant mesenchymal neoplasm whose intracavitary appearance may mimic other cardiac masses. We report a woman in her early 60s with recurrent palpitations and occasional exertional dyspnea. Transthoracic echocardiography (TTE) demonstrated a giant, highly mobile, irregular multilobulated mass occupying most of the left ventricular cavity, with slit-like interlobular clefts and a probable broad-based attachment near the apical interventricular septum. Low-velocity color Doppler demonstrated residual flow around and between lobules, while continuous-wave Doppler showed a peak left ventricular outflow tract velocity of 3.09 m/s and a peak instantaneous gradient of 38 mmHg. Cardiac computed tomography angiography (CTA) showed a large relatively hypoattenuating left ventricular mass with heterogeneous enhancement: some portions showed no obvious enhancement, whereas others showed mild enhancement; the interface with the ventricular wall was locally indistinct, so myocardial involvement could not be excluded. After induction of general anesthesia, intraoperative transesophageal echocardiography (TEE) showed the mass nearly filling the left ventricular cavity, but the attachment and fine multilobulated architecture were less clearly seen than on preoperative TTE. The patient underwent tumor resection with concomitant mitral valve repair. Histology showed mildly atypical spindle cells with fascicular and focal perivascular growth, readily identified mitotic figures, and mild myxoid stromal change. Immunohistochemistry showed MDM2 positivity, and fluorescence in situ hybridization demonstrated MDM2 and CDK4 amplification, supporting the diagnosis of intimal sarcoma. At approximately 2 weeks after surgery, follow-up TTE showed no residual or recurrent left ventricular mass, preserved left ventricular systolic function, minimal residual mitral regurgitation, and a peak outflow tract velocity of 0.92 m/s without residual obstruction. Postoperative 18F-FDG PET/CT performed at approximately the same time identified no definite extracardiac primary tumor or obvious distant metastatic lesions. The case illustrates how multimodality imaging can define the anatomy and hemodynamic effects of a rare left ventricular intimal sarcoma, while histopathologic and molecular findings remain essential for definitive diagnosis.

PMID 42876770
Read full article →
PubMedJournal of asthma and allergy2026-10-14

Dosing Calculations in Prescribing Sublingual Immunotherapy Drops Using Subcutaneous Immunotherapy Extracts: Implications for Dust Mite and Cat Immunotherapy.

Gendo Karna K, Gilbert Katherine K, Jacobs Joshua J, Mozelsio Nancy N et al.

Sublingual immunotherapy drops (SLIT-D) in the US commonly use extracts manufactured for subcutaneous immunotherapy (SCIT). Using a target daily major allergen dose together with the extract major allergen concentration allows calculation of the extract volume necessary for a maintenance SLIT vial. Although an optimal universal SLIT-D dose has not been established, published dosing recommendations provide practical benchmarks for illustrating these calculations. Using an illustrative target of 15 µg/day in an 8-mL vial, cat extract containing 20 µg/mL Fel d 1 would require 24 mL, whereas dust mite extract containing 60 µg/mL Der p 1 would require 8 mL. This Commentary presents a practical dose-estimation framework based on published allergen concentration data and highlights how lower major-allergen concentrations may constrain SLIT-D formulation.

PMID 42871330
Read full article →
PubMedFungal biology2026-10-14

Critical role of AaTgl1 lipase/hydrolase in virulence and lesion formation in Alternaria alternata.

Parco Jessalyn Marasigan JM, Choo Celine Yen Ling CYL, Lu Hsin-Yu HY, Wu Pei-Ching PC et al.

Lipases and hydrolases play important roles in diverse biological processes in fungi. Their roles in virulence in the phytopathogenic fungus Alternaria alternata remain poorly understood. The AaTgl1 protein of A. alternata is a putative lipase/hydrolase characterized by a triacylglycerol lipase domain, an α/β-hydrolase superfamily domain, and a catalytic triad (Ser353, Asp522, His548) within the conserved GxSxG motif. Sequence analysis revealed only 64-68% similarity to orthologs from other filamentous fungi, suggesting a specialized role in lipid metabolism that may contribute to the ecological success of Alternaria. Targeted deletion of AaTgl1 (ΔAaTgl1) demonstrated its essential role in fungal development: mutants exhibited reduced vegetative growth, impaired conidiation, defective germination, and diminished formation of appressorium-like structures. Genetic complementation restored wild-type phenotypes, confirming the specific requirement for AaTgl1. Lipid droplet staining showed that AaTgl1 is indispensable for lipid storage and mobilization. ΔAaTgl1 accumulated elevated levels of reactive oxygen species, exhibited heightened sensitivity to oxidative stress, and displayed increased cell wall damage, implicating AaTgl1 in redox homeostasis and structural integrity. Although dispensable for toxin biosynthesis, ΔAaTgl1 showed markedly attenuated virulence on calamondin leaves, suggesting a role in overcoming host defenses. Collectively, these findings indicate that AaTgl1 is a multifunctional lipase/hydrolase that integrates lipid metabolism, stress tolerance, and morphogenesis, thereby serving as a critical determinant of fungal fitness and pathogenicity in A. alternata. This study provides new insights into the molecular mechanisms linking lipid regulation to fungal development, host adaptation, and virulence.

PMID 42875110
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about alternaria allergen SLIT